Comparative Pharmacology
Head-to-head clinical analysis: FLUCONAZOLE IN DEXTROSE 5 IN PLASTIC CONTAINER versus VAGISTAT 1.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FLUCONAZOLE IN DEXTROSE 5 IN PLASTIC CONTAINER versus VAGISTAT 1.
FLUCONAZOLE IN DEXTROSE 5% IN PLASTIC CONTAINER vs VAGISTAT-1
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Fluconazole selectively inhibits fungal cytochrome P450-dependent enzyme lanosterol 14-α-demethylase, thereby blocking the conversion of lanosterol to ergosterol, an essential component of the fungal cell membrane. This leads to increased membrane permeability and inhibition of fungal growth.
Tioconazole is an imidazole antifungal that inhibits fungal cytochrome P450 14α-demethylase, thereby blocking the conversion of lanosterol to ergosterol, a key component of the fungal cell membrane. This disrupts membrane integrity and fungal growth.
200-400 mg IV once daily; for candidemia or invasive candidiasis, loading dose of 800 mg IV on day 1, then 400 mg IV once daily.
One 300 mg vaginal suppository administered as a single dose.
None Documented
None Documented
Terminal elimination half-life approximately 30 hours (range 20-50 hours). Prolonged in renal impairment (up to 98 hours in CrCl <20 mL/min).
The terminal elimination half-life is approximately 5-7 days, reflecting prolonged vaginal retention and slow systemic absorption.
Renal: 80% unchanged drug; feces: 11%; biliary: minor.
Approximately 50% is excreted unchanged in feces via biliary elimination; less than 1% is excreted unchanged in urine.
Category A/B
Category C
Azole Antifungal
Azole Antifungal